Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 7/20 | 0.75 |
| ▸ | MCL1 | Q07820 | 7/20 | 0.36 |
| ▸ | NOS1 | P29475 | 2/20 | 0.36 |
| ▸ | NOS2 | P35228 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | BCL2 | P10415 | 1/20 | 0.35 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3108568 | 0.85 | CYP2D6 (1.00) | CYP2D6MCL1IMPDH2SYKALDH1A1 | |
| SCHEMBL3096296 | 0.82 | CYP2D6 (0.79) | CYP2D6MCL1HTT | |
| SCHEMBL3099144 | 0.81 | CYP2D6 (0.91) | CYP2D6MCL1IMPDH2ALDH1A1MAPT | |
| SCHEMBL13097702 | 0.79 | CYP2D6 (0.73) | CYP2D6ALDH1A1MAPTHTT | |
| SCHEMBL13097710 | 0.78 | CYP2D6 (0.71) | CYP2D6MCL1USP2ALDH1A1MAPT | |
| SCHEMBL13097656 | 0.77 | CYP2D6 (0.79) | CYP2D6MCL1 | |
| SCHEMBL13097687 | 0.76 | CYP2D6 (0.70) | CYP2D6NOS1NOS2CYP2C9 | |
| SCHEMBL13097741 | 0.75 | CYP2D6 (0.64) | CYP2D6USP2ALDH1A1MAPTHPGD | |
| SCHEMBL13097689 | 0.75 | CYP2D6 (0.82) | CYP2D6IMPDH2ALDH1A1MAPT | |
| SCHEMBL3103496 | 0.75 | CYP2D6 (0.81) | CYP2D6MCL1IMPDH2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367702-B2 | Quinolone derivative | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-8367702-B2 | Quinolone derivative | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20100256113-A1 | QUINOLONE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-20100256113-A1 | QUINOLONE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2194044-A1 | QUINOLONE DERIVATIVE | Astellas Pharma Inc. (JP) | 2010-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256113-A1 | QUINOLONE DERIVATIVE | NQO1, NQO2, NADK | CYP2D6 230/4885MCL1 3783/4885NOS1 797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.